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Background. Exercise-induced bronchospasm (EIB) affects up to 90% of all patients with asthma. Objective. This study evaluated the ability of
levalbuterol hydroﬂuoroalkane (HFA) 90 µg (two actuations of 45 µg) administered via metered dose inhaler (MDI) to protect against EIB in mild-
to-moderate asthmatics. Methods. This was a randomized, double-blind, placebo-controlled, two-way cross-over study. Patients with asthma (n = 15)
were ≥18 years, had a ≥6-month history of EIB, ≥70% baseline predicted forced expiratory volume in 1 second (FEV1), and a 20% to 50% decrease
in FEV1 after treadmill exercise challenge using single-blind placebo MDI. Levalbuterol or placebo was self-administered 30 minutes before exercise.
Treatment sequences were separated by a 3- to 7-day washout period. Spirometry was performed predose, 20 minutes postdose/pre-exercise, and 5,
10, 15, 30, and 60 minutes post-exercise. The primary endpoint was the maximum percent decrease in FEV1 from baseline (postdose/pre-exercise).
The percentage of protected (≤20% decrease in post-exercise FEV1) patients was also assessed. Results. Levalbuterol had signiﬁcantly smaller
maximum percent post-exercise decrease in FEV1 compared with placebo (LS mean ± SE; −4.8% ± 2.8% versus −22.5% ± 2.8%, respectively). For
levalbuterol, 14/15 (93.3%) patients had <20% decrease in post-exercise FEV1 compared with 8/15 (53.3%) for placebo (p = 0.0143). Treatment was
well tolerated. Conclusion. Levalbuterol HFA MDI (90 µg) administered 30 minutes before exercise was signiﬁcantly more effective than placebo
in protecting against EIB after a single exercise challenge and was well tolerated. Clinical Implications. Levalbuterol HFA MDI when administered
before exercise was effective in protecting adults with asthma from EIB.
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INTRODUCTION
Exercise-induced bronchospasm (EIB) is a common con-
dition occurring in up to 90% of patients with asthma and in
upto10%ofpatientsthatarenotknowntobeasthmatic(1,2).
EIB is an acute transient airway narrowing that occurs some-
timesduringorveryoftenafterexercise.Itisthoughttobeini-
tiated by abrupt changes in airway temperature and humidity
during exercise (1). It is particularly common in children and
young adults (3), most likely due to their higher physical ac-
tivity.EIBoftenresultsinaffectedpersonswithdrawingfrom
physical activity (4–6). The current asthma treatment guide-
lines recommend pre-treating EIB by administering short-
acting β2-agonists shortly before exercise, which can protect
over 80% of the patients (7).
Two commonly prescribed short-acting β2-agonists used
for treating asthma are racemic albuterol and levalbuterol.
Racemic albuterol is a 1:1 mixture of (R)- and (S)-albuterol.
The (R)-albuterol enantiomer is responsible for the bron-
choprotective and bronchodilatory properties of racemic al-
buterol (8, 9). Levalbuterol is the (R)-albuterol enantiomer
and is available as a hydroﬂuoroalkane (HFA) metered dose
inhaler (MDI) or as a solution for nebulization. Pre-clinical
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studies suggest that (S)-albuterol may be pro-inﬂammatory
and pro-constrictive and may attenuate the beneﬁcial effects
of (R)-albuterol (10). The clinical relevance of these data for
the treatment of asthma is not clear.
Several studies have demonstrated the ability of racemic
albuterol MDI to protect against EIB (11–15). Although the
FDA has not approved levalbuterol HFA MDI to treat EIB,
we were interested in evaluating the protective effect of lev-
albuterol in asthmatics. This is the ﬁrst reported study to
investigate and describe that effect.
METHODS
Study Design
This was a randomized, double-blind, placebo-controlled,
multicenter, two-way cross-over study designed to evaluate
the efﬁcacy of levalbuterol HFA MDI (90 µg; two actuations
of 45 µg each) versus placebo in subjects with asthma 18
years of age and older with EIB. The study was conducted
according to the principles established by the Declaration of
Helsinki. The appropriate Institutional Review Boards ap-
proved the protocol, and written informed consent was ob-
tained from the patients.
Study Patients
Eligible patients were required to be ≥18 years of age
with stable asthma; have a forced expiratory volume in 1
second (FEV1) ≥70% of predicted, and have been using β2-
adrenergic agonists, anti-asthma, anti-inﬂammatory medica-
tion, or over-the-counter asthma medication for at least 6
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TABLE 1.—Demographics and baseline characteristics.
ITT population (n = 15)
Age, yr, mean (SD) 30.5 (9.0)
Male, n (%) 13 (86.7)
Race, n (%)
Caucasian 15 (100)
FEV1, (L), mean (SD) 3.8 (0.6)
% Predicted FEV1, mean (SD) 86.5 (9.2)
Maximum% decrease in FEV1
postdose/pre-challenge at screening, mean
(SD)
−26.5 (7.0)
Patients with allergic rhinitis, n (%) 15 (100)
Concomitant medication during the double
blind period, n (%)
Montelukast sodium 1 (6.7)
Inhaled corticosteroids 5 (33.3)
Antihistamines 2 (13.3)
months. Patients were required to have a documented his-
tory of EIB for a minimum of 6 months and a decrease in
FEV1 of at least 20% but no more than 50% after a dose
of single blind placebo MDI (HFA-134a propellant contain-
ing ethanol and oleic acid; two actuations) and a baseline
exercise challenge. One patient with a maximum percent de-
crease in FEV1 of 19% was included in the study. Patients
were ineligible if they were diagnosed with life-threatening
asthma (intubation, hypercapnia, respiratory arrest, hypoxic
seizures) within 12 months before the ﬁrst study visit. They
were also not eligible if they had been hospitalized with
asthma within 4 weeks of the ﬁrst visit or had a signiﬁ-
cant upper or lower respiratory infection 3 weeks before the
ﬁrst study visit. Patients were excluded if they had a docu-
mentedhistoryofbronchopulmonaryaspergillosisorallergic
alveolitis or had greater than 10-pack-year history of smok-
ing or tobacco product use within 6 months of the initial
visit.
Medications that were disallowed during the entire study
period included parenteral or oral corticosteroids, all adren-
ergic bronchodilators (except the study medication), non-
prescription asthma medication, and ipratropium bromide.
Leukotriene inhibitors and low to moderate doses (≤660
µg ﬂuticasone/day or ≤800 µg beclomethasone/day) of in-
haled corticosteroids were allowed provided the patient was
maintained on a stable dose 30 days before visit 1. Inhaled
corticosteroids were withheld for 10 hours before each study
visit.Antihistamineswerealsoallowedbuthadtobewithheld
for 48 hours before each study visit.
Study Protocol
The study consisted of three visits, each separated by 3
to 7 days. At the screening visit (visit 1), all baseline val-
ues were obtained. This included an exercise challenge to
conﬁrm the diagnosis of EIB per protocol limits. At visit
2, patients were randomly assigned to one of two treat-
ments (levalbuterol HFA MDI [90 µg, two actuations of
45 µg each] or placebo [HFA-134a propellant containing
ethanol and oleic acid; two actuations]). Randomization oc-
curred separately within each site using permutated blocks
of four. At visit 3 patients were crossed-over to the alternate
treatment. At visit 1, subjects received an open-label leval-
buterol HFA MDI to be used as rescue medication during
the study. Rescue medication was used as-needed except on
the day of a clinic visit when it was withheld for at least 8
hours before the visit. Patients also received medical event
calendars for monitoring adverse events and concomitant
medication.
A standard exercise challenge on a treadmill was per-
formedat30minutespostdose(16).Duringtheexercisechal-
lenge, the gradient and speed of the treadmill were adjusted
at 1-minute intervals to achieve at least 85% of the subject’s
maximum predicted heart rate (calculated as 220 minus the
patient’s age). At the qualifying exercise challenge (visit 1),
the settings for the treadmill rate and incline at each time in-
terval were recorded. These settings were used for the initial
settingsateachsubsequentexercisechallengewithminorad-
justmentstomaintainthesubject’stargetmaximumheartrate
(85% of maximum). The exercise challenge was concluded
when patients maintained the target heart ratefor a minimum
of 4 minutes. The subject could also stop the test at any time.
To control for temperature and humidity of the inspired air
during the exercise challenge, subjects inspired compressed
dry air at room temperature through a Hans Rudolph Nasal
andMouthBreathingFaceMaskwithaT-shapeconﬁguration
and a Two-Way Non-Rebreathing Valve (Hans Rudolf, Inc.,
Kansas City, Missouri, USA). The temperature of the room
was maintained between 68◦Ft o7 7 ◦F.
Before the exercise challenge, patients self-administered
(two actuations) single-blind placebo MDI (visit 1) or ran-
domized double-blind medication (visits 2 and 3). The MDI
was primed (four test sprays) before use by study person-
nel before dispensing and the subject was instructed on its
properuse.Studypersonnelmonitoredproperadministration
ofthedrug.Spirometrywasperformedpredose/pre-exercise,
20minutespostdose/pre-exercise(e.g.,10minutesbeforeex-
ercise),andat5,10,15,30,and60minutespost-exercise(±1
minute). After 60 minutes, spirometry measurements contin-
ued every 15 minutes until the subject returned to within 5%
of the predose FEV1.I fthe subject’s FEV1 values did not
return to the pre-exercise level within 4 hours, the visit was
concluded at the Investigator’s discretion. A ﬁnal FEV1 was
measured before discharge.
Heart rate was monitored each minute during exercise. Vi-
tal signs were measured before and immediately after ex-
ercise challenge, before the 30- and 60-minute spirometry
measurements, and at discharge. Adverse events were col-
lected from the time of informed consent to the end of
study.
The primary endpoint was the maximum percent decrease
in FEV1 from visit postdose/pre-challenge FEV1. Secondary
endpoints included the time to FEV1 recovery after exer-
cise challenge (deﬁned as the amount of time post-challenge
needed for FEV1 to return to within 5% of the postdose/pre-
challengevalue),themeanpercentchangeinFEV1 fromvisit
predose to postdose/pre-challenge to post exercise, and the
number of protected/unprotected patients. Protected patients
were deﬁned as those who had less than a 20% decrease
in FEV1. These values were based on guidelines (USDHHS
Guidance for Industry) that consider patients with a greater
than20%decreaseinFEV1 afterexercisechallengeasnotbe-
ing protected from EIB (17). Analyses of protection at other
levels (15% and 10%) considered by other investigators to
be protective (16, 18) were also analyzed. Safety endpoints
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Statistical Analysis
Assuming a within-subject standard deviation of 12 per-
centage points and based on a two-tailed test with α = 0.05,
a sample size of 14 subjects was determined to provide at
least 80% power to detect a difference of 10% points in the
maximum percent decrease in FEV1 from visit postdose/pre-
challenge between the two treatment groups. The intent-to-
treat (ITT) population consisted of all randomized subjects
who received at least one dose of study medication. All
efﬁcacy and safety analyses were performed on the ITT
population.
The primary endpoint, the maximum percent FEV1 de-
crease from visit postdose/pre-challenge, was analyzed us-
ing a mixed model analysis of variance with the maximum
percent FEV1 decrease as the dependent variable, sequence,
treatment, period, and postdose/pre-challenge FEV1 as ﬁxed
effects, and patient as a random effect (19, 20). The time
to FEV1 recovery and the number of subjects with less than
10%,10%to20%,andmorethan20%decreaseinFEV1 were
summarized by treatment. Other secondary endpoints were
analyzed using the same mixed model as the primary end-
point. Percent change from pre-dose and visit predose/post-
challenge was summarized for FEV1 over time by treatment.
The frequency of rescue medication and percent of subjects
with adverse events were summarized by treatment.
RESULTS
Of 23 patients screened for the study, 15 met the protocol
criteria and were randomized to treatment and all 15 com-
pletedthestudy.Themeanagewas30.5yearsandthemajor-
ity (n = 13) were male (Table 1). Patients had mild-moderate
asthma (mean FEV1 86% of predicted), and all had docu-
mented EIB. At study entry, 5/15 (33%) of patients were on
inhaled corticosteroids.
Spirometry Measurements
The maximum percent decrease in FEV1 from visit
postdose/pre-challenge (primary endpoint) was signiﬁcantly
less in patients treated with levalbuterol compared with
placebo (LS mean ± SE: −4.8% ± 2.8% and −22.5%
± 2.8%, respectively; p = 0.0002) (Figure 1A). The mean
decrease in FEV1 from postdose/pre-challenge at each time
point after exercise was also less for levalbuterol than for
placebo (Figure 2). More patients were protected against
EIB with levalbuterol than placebo. Only 1 of 15 (6.7%)
patients (patient 2; see Table 2) treated with levalbuterol had
a more than 20% decrease in FEV1 compared with 7 of 15
(46.7%) patients for placebo (Figure 1B). In contrast, 12 of
15(80%)patientsafterlevalbuterolusehadlessthan10%de-
crease in FEV1 compared with 2 of 15 (13.3%) for placebo
(Figure 1B). The mean time for FEV1 recovery was faster
with levalbuterol (15.0 minutes) compared with placebo
(46.4 minutes).
Levalbuterol was associated with signiﬁcantly greater
bronchodilation before exercise compared with placebo.
LS mean (SE) percent change in FEV1 from predose to
postdose/pre-challenge was 9.4 ± 1.1 for levalbuterol com-
paredwith0.3±1.1forplacebo(p<0.0001).Afterexercise
following levalbuterol treatment, the maximum percent de-
crease in FEV1 values for the majority (9 of 15) of individual
FIGURE 1.—(A) Maximum percent decrease in FEV1 for each patient from
postdose/pre-challenge after treatment with placebo (DB-placebo) or leval-
buterol(DB-levalbuterol)duringthedouble-blindperiodforeachpatient.Patient
numbers (see Table 2) are indicated and the solid grey lines are to aid following
individual patient values. LS-mean (Least square mean) is the adjusted means
for the effects in the model (see methods). (B) Percent of patients protected at
10%, 15%, and 20% is indicated.
patientsdidnotfallbelowpredoselevels(Table2).Moreover,
the mean FEV1 did not fall below predose levels (Figure 2).
In contrast after exercise following placebo treatment, the
maximum percent decrease in FEV1 values for the major-
ity (14 of 15) of patients fell below predose values (Table
2). Post-exercise, the mean FEV1 after placebo treatment
dropped below predose values. The LS mean (SE) for the
maximum percent decrease in FEV1 from predose to post-
exercise was 9.8 ± 2.2 for levalbuterol and −4.2 ± 2.2 for
placebo (p = 0.0008).
There was some intrapatient variability in response to ex-
ercise challenge. For a number of patients, the changes in
FEV1 post-exerciseforthetwoplacebotreatments(atscreen-
ing [visit 1] and the double-blind period) were dissimilar
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TABLE 2.—Maximum percent decrease in FEV1 after exercise from two different baselines: postdose/pre-challenge and predose.∗
Visit postdose/pre-challenge at baseline Visit pre-dose at baseline
Screening visit Screening visit
Patients (placebo) DB-placebo DB-levalbuterol (placebo) DB-placebo DB-levalbuterol
1 −42.6 −24.3 −0.9 −41.7 −25.8 0.0
2 −40.8 −54.1 −21.3 −40.8 −55.7 −1.5
3 −31.0 −31.6 −6.8 −31.2 −33.0 0.0
4 −30.0 −44.9 −0.2 −28.1 −42.8 0.0
5 −27.4 −30.4 −4.5 −27.8 −29.5 0.0
6 −26.4 −16.2 −12.0 −27.5 −18.3 −4.0
7 −25.6 −20.4 −8.8 −26.5 −20.8 0.0
8 −23.4 −16.3 −7.4 −21.0 −17.1 −5.7
9 −23.2 0.0 0.0 −24.6 0.0 0.0
10 −22.9 −24.1 −4.0 −21.5 −20.0 0.0
11 −21.2 −8.0 −10.6 −22.5 −7.3 −5.3
12 −21.3 −14.8 −0.5 −20.3 −15.5 0.0
13 −20.5 −17.6 0.0 −16.9 −18.3 0.0
14 −22.4 −11.7 −4.6 −20.7 −8.9 −0.6
15 −19.0 −12.7 −5.8 −19.4 −13.4 −2.5
Mean (SD) −26.5 (7.0) −21.8 (14.0) −5.8 (5.8) −26.0 (7.3) −21.8 (14.2) −1.3 (2.1)
∗DB-placebo and DB-levalbuterol indicates the placebo or levalbuterol treatment, respectively, during the double-blind period of the study.
Afterplacebotreatment,threepatientsrequiredonedoseof
rescuemedicationafterexercisechallengeduringthedouble-
blindperiodofthestudy,andnopatientsrequiredrescuemed-
ication after levalbuterol treatment. There was no signiﬁcant
difference in heart rate or respiration rates with levalbuterol
and placebo treatments after exercise (data not shown).
Adverse Events
There were four adverse events observed. The reported
post-randomization adverse events after levalbuterol treat-
ment were myalgia (n = 2) and vomiting (n = 1), and after
placebo treatment nasopharyngitis (n = 1). None were con-
sidered by the investigators to be related to treatment. There
were no serious adverse events reported during the study.
FIGURE 2.—The mean FEV1 predose, postdose/pre-exercise challenge, and at
each time point post-exercise after treatment with levalbuterol or placebo. The
standard deviation for each point is indicated.
DISCUSSION
We examinedtheabilityoflevalbuterolHFA90µgadmin-
istered through an MDI to protect adults with asthma from
EIB.LevalbuterolHFAtaken30minutesbeforetreadmillex-
ercise was found to be protective. The mean maximum per-
centdecreaseinFEV1 frompostdose/pre-challenge(primary
endpoint) was signiﬁcantly smaller (p < 0.001) for leval-
buterol treatment than for placebo. All but 1 of 15 subjects
wereprotectedfromEIBwhenusinglevalbuterolwithamax-
imumdecreaseinFEV1 oflessthan20%,acriteriasuggested
by the USDHHS Guidance for Industry (17). Although the
decrease in FEV1 was greater than 20% for one patient (pa-
tient#2),thispatientstillhadalargedegreeofprotectionfrom
EIBafterlevalbuteroltreatment,(maximumpercentdecrease
in FEV1 following DB-Placebo was −54.1% compared with
−21.3% following DB-Levalbuterol) (Table 2). The fact that
levalbuterol improved post-exercise FEV1 by 32.8% but the
decrease was still greater than 20% may reﬂect the very low
baseline value for this patient (decrease in FEV1 after DB-
Placebo treatment). All other measurements of pulmonary
function, including mean percent change in FEV1 at all time
points post-exercise and time to FEV1 recovery (baseline),
were supportive of the effective protection against EIB by
levalbuterol.Noneofthethreeinstancesinwhichrescuemed-
ication related to exercise challenges was required occurred
when levalbuterol was used pre-challenge.
The degree of protection from EIB can be considered clin-
ically important. After levalbuterol treatment, the majority
of patients were protected (12 of 15 had less than a 10% de-
crease in FEV1 and 14 of 15 had less than a 15% decrease
after exercise). In contrast after placebo treatment, most pa-
tients were not protected against EIB (2 of 15 had less than
a 10% decrease in FEV1 and 5 of 15 had less than 15% de-
crease post-exercise). A 10% decrease in FEV1 is considered
to be indicative of healthy non-asthmatic subjects (18, 21–
23), while a 15% or greater fall in FEV1 is considered by
some investigators and guidelines as a diagnosis of EIB.
Protection by levalbuterol was also associated with a
rapidbronchodilatingeffectachievedpre-exercisechallenge.
Although postdose/pre-challenge has been a commonly used
baseline (17), others have suggested predose to be a more
appropriate baseline (24, 25). However, with the exceptionEVALUATION OF LEVALBUTEROL HFA MDI IN EIB 733
of one patient, in this study, the degree of bronchodilation af-
ter exercise from postdose/pre-challenge was not sufﬁciently
different from predose to alter the conclusions of the study if
predosewasusedforbaseline(datanotshown).Theduration
of the protective effect of levalbuterol was not examined in
this study.
Asthma is characterized by differences between patients
and by intrapatient variability both over short and long pe-
riods of time (17). In this study, variability in a patient’s
response was apparent by the difference in percent change
in FEV1 between the screening and the double-blind placebo
treatments (Table 2). In this context, prescribing physicians
as well as patients need to appreciate the potential variability
in degree of protection by a single dose of bronchoprotective
agentsusedbeforeexercise.Moreover,consistent(e.g.,daily)
use of β-adrenergic agents can lead to relative tolerance to
the bronchoprotective effect of these agents (15, 26–29), al-
though intervals of use of 72 hours or greater abrogate this
effect (28). Long-term anti-inﬂammatory control of asthma
can decrease bronchial reactivity to various asthma triggers
such as exercise (30–33).
Conclusion
This is the ﬁrst reported evaluation of the ability of leval-
buterolHFAMDIusedassingledosepre-treatmenttoprotect
patients from EIB. It was found that a single dose adminis-
tered 30 minutes before exercise was effective in protecting
against EIB and was well tolerated.
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